Daiichi Sankyo Company has dosed the first patient in the first in a Phase I trial evaluating the safety and activity of quizartinib in combination with milademetan (DS-3032) to treat patients with relapsed / refractory FLT3-ITD acute myeloid leukemia (AML).
The multi-centre, non-randomised, open-label trial will be conducted in two parts and will include newly-diagnosed FLT3-ITD AML patients who are unfit for intensive chemotherapy.
Part one of the study (dose escalation) will investigate the safety and tolerability of the drug combination to establish the dosing schedule, maximum tolerated dose and recommended dose for expansion.
The trial’s second part (dose expansion) will validate the safety and tolerability at the recommended dose for expansion of the study drug combination. This phase will also identify a recommended Phase II dose.
Primary endpoint of the trial is safety, while its secondary endpoints include pharmacokinetics and preliminary efficacy.
Daiichi Sankyo aims to enrol around 110 patients in the US, Europe and Japan.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Daiichi Sankyo Oncology research and development vice-president Arnaud Lesegretain said: “We have initiated this combination study of quizartinib and milademetan in order to determine the safety and tolerability of the combination and if the addition of the MDM2 inhibitor milademetan may potentially further improve the outcomes of patients with relapsed / refractory FLT3-ITD AML beyond what has been previously reported with single agent quizartinib.
“In this study, we also are exploring the potential of the combination of quizartinib and milademetan in patients with newly-diagnosed FLT3-ITD AML who are unfit for intensive chemotherapy.”
Quizartinib is a FMS-like tyrosine kinase 3 (FLT3) inhibitor, while milademetan is a mouse double minute 2 homolog (MDM2) inhibitor.